DGAP-News
INJEX Pharma AG: Strategic Financial Group invests in INJEX Pharma AG - Seite 2
refer to www.injex.com. For further questions please contact our Investor
Relations team directly:
INJEX Pharma AG
Investor Relations-Team
t: +49 89 24 41 18 - 223
f: +49 89 24 41 18 - 228
ir@injex.de
INJEX Pharma AG:
INJEX Pharma Aktiengesellschaft and its subsidiaries INJEX Pharma GmbH and
INJEX Vertrieb Deutschland GmbH are specialized in the development,
manufacturing and marketing in the medical technology segment and in the
cosmetics and beauty markets. The Group's core business areas are the
needle-free INJEX30 system and the product line SHIREEN in the beauty
market. The main markets of the Group are North America, China, India,
Russia and Europe.
End of Corporate News
---------------------------------------------------------------------
17.12.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: INJEX Pharma AG
Buckower Damm 114
12349 Berlin
Germany
Phone: +49 89 24 41 18 - 223
Fax: +49 89 24 41 18 - 499
E-mail: ir@injex.de
Internet: www.injex.de
ISIN: DE000A0STYL7
WKN: A0STYL
Listed: Regulierter Markt in Frankfurt (General Standard)
Notierung im Regulierten Markt vorgesehen / intended to be
listed at Regulated Market
End of News DGAP News-Service
---------------------------------------------------------------------
245122 17.12.2013
INJEX Vertrieb Deutschland GmbH are specialized in the development,
manufacturing and marketing in the medical technology segment and in the
cosmetics and beauty markets. The Group's core business areas are the
needle-free INJEX30 system and the product line SHIREEN in the beauty
market. The main markets of the Group are North America, China, India,
Russia and Europe.
End of Corporate News
---------------------------------------------------------------------
17.12.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: INJEX Pharma AG
Buckower Damm 114
12349 Berlin
Germany
Phone: +49 89 24 41 18 - 223
Fax: +49 89 24 41 18 - 499
E-mail: ir@injex.de
Internet: www.injex.de
ISIN: DE000A0STYL7
WKN: A0STYL
Listed: Regulierter Markt in Frankfurt (General Standard)
Notierung im Regulierten Markt vorgesehen / intended to be
listed at Regulated Market
End of News DGAP News-Service
---------------------------------------------------------------------
245122 17.12.2013